Core Viewpoint - The company, Gilead Sciences-B (01672), has seen a significant stock price increase of over 7%, currently trading at 11.62 HKD with a transaction volume of 56.46 million HKD, following the announcement of a share buyback plan using up to 300 million HKD [1] Group 1: Share Buyback Announcement - The board of directors has decided to exercise the buyback authorization and will repurchase shares in the open market based on market conditions [1] - The company plans to utilize a maximum of 300 million HKD for the proposed share buyback [1] Group 2: Clinical Data and Future Plans - Dongwu Securities has indicated that the company has multiple catalysts in the second half of the year, with several important clinical data releases expected [1] - The company is anticipated to report top-line data for ASC30 oral Phase II, ASC47 Phase I, and ASC50 Phase I by Q4 2025, and for ASC30 subcutaneous Phase II by Q1 2026 [1] - The company expects to submit 2-3 new IND applications to the FDA within the next 6-9 months, including a dual-target peptide weight loss pipeline [1]